Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.


Slider News


  • 2022 - 01 - 17

    Menarini Diagnostics CoronaMeltVAR Real-Time PCR kit simultaneously detects SARS CoV-2 and identifies the Omicron Variant

  • 2022 - 02 - 02

    Conversations with Nobel Prize Winners: The Fondazione Menarini launches their “Dialogs Beyond Borders” series

  • 2022 - 03 - 14


  • 2022 - 05 - 08

    Raffaello, maestro di armonia e difensore dei beni culturali protagonista del volume d’arte di Menarini

  • 2022 - 05 - 09

    Berlin-Chemie Menarini’s position in Ukraine

  • 2022 - 05 - 20

    Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology

  • 2022 - 05 - 20

    Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO<sup>®</sup> (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

  • 2022 - 05 - 26

    Menarini inaugurates new regional headquarters in Dubai, UAE

  • 2022 - 06 - 06

    Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

  • 2022 - 06 - 07

    Premio Internazionale Fair Play Menarini, assegnato il Premio speciale Fiamme Gialle “Studio e sport”

  • 2022 - 06 - 22

    Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

  • 2022 - 06 - 23

    The XXVI Fair Play Menarini International Award opens with a press conference at CONI

  • 2022 - 06 - 28

    NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe

  • 2022 - 06 - 30

    Il Premio Internazionale Fair Play Menarini arriva a Firenze, presentata la XXVI edizione a Palazzo Vecchio

  • 2022 - 07 - 04

    Il XXVI Premio Internazionale Fair Play Menarini debutta a Firenze, “I campioni si raccontano” in diretta tv dal Salone dei Cinquecento

  • Fair Play Menarini

    2022 - 07 - 06

    Premio Internazionale Fair Play Menarini: dopo “I campioni si raccontano” la cena di gala in attesa della cerimonia di premiazione

  • 2022 - 07 - 07

    Sport’s finest gather under the stars for the grand finale of the XXVI Fair Play Menarini International Award

  • 2022 - 07 - 21

    Karyopharm and Menarini Receive Full Marketing Authorisation from the European Commission for NEXPOVIO<sup>®</sup> (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy

  • 2022 - 08 - 02

    Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

  • 2022 - 08 - 04

    ATGC Co., Ltd. License Agreement Grants RELIFE S.r.l. Exclusive Rights to Register, Promote, Distribute, and Market the Novel Botulinum Toxin Type A (ATGC-100) in Europe and the United Kingdom.

  • 2022 - 08 - 11

    Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

  • 2022 - 08 - 19

    Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

  • 2022 - 09 - 08

    Nasce ON RADAR il laboratorio di pensieri, idee, dialogo

  • 2022 - 10 - 14

    Giorgione: Maestro di mistero, tra Rinascimento e modernità. Domani a Venezia la presentazione del volume d'arte di Menarini dedicato all'artista

  • 2022 - 11 - 01

    Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

  • 2022 - 11 - 02

    QuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POC™ Platform

  • 2022 - 11 - 24

    Le Volpi Rosse Menarini continuano la loro avventura in Serie A

  • 2022 - 11 - 29

    Lost childhood: a 'tight-knit' network to combat abuse and distress

  • 2022 - 11 - 30

    Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS)

  • 2022 - 12 - 14

    Circulating Tumor Cell detection by Menarini Group’s CELLSEARCH<sup>®</sup> System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early

  • 2022 - 12 - 19

    Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination